Rabe E, Breu F, Cavezzi A, Smith PC, Frullini A, Gillet J, Guex J, Hamel-Desnos C, Kern P, Partsch B, Ramelet A, Tessari L, Pannier F; for the Guideline Group. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2013; Epub ahead of print DOI: 10.1177/0268355513483280.
2.
GilletJL. Foam sclerotherapy of saphenous veins — Results and side effects. Reviews in Vascular Medicine2013; 1: 24–29.
3.
RathbunSNorrisAStonerJ. Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders. Phlebology2012; 27: 105–117.
4.
RabeEOttoJSchliephakeDPannierF. Efficacy and Safety of Great Saphenous Vein Sclerotherapy Using Standardised Polidocanol Foam (ESAF): A Randomised Controlled Multicentre Clinical Trial. Eur J Endovasc Vasc Surg2008; 35: 238–245.
5.
GuexJJAllaertF-AGilletJ-L. Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg2005; 31: 123–128.
6.
GilletJLGuedesJMGuexJJ. Side effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1025 patients. Phlebology2009; 24: 131–138.
7.
CavezziAParsiK. Complications of foam sclerotherapy. Phlebology2012; 27(Suppl 1): 46–51.
8.
SarvananthanTShepherdACWillenbergTDaviesAH. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg2012; 55: 243–251.
9.
ParsiK. Paradoxical embolism, stroke and sclerotherapy. Phlebology2012; 27: 147–167.
GilletJLDonnetALauseckerMGuedesJMGuexJJLehmannP. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology2010; 25: 261–266.
12.
FrulliniABarsottiMCSantoniTDurantiEBurchielliSDi StefanoR. Significant endothelin release in patients treated with foam sclerotherapy. Dermatol Surg2012; 38: 741–747.
13.
GilletJL. Neurological complications of foam sclerotherapy: fears and reality. Phlebology2011; 26: 277–279.
14.
GilletJL. Letter to the Editor. Three cases of stroke following peripheral venous interventions. Phlebology2013, pp. 28–55.
15.
JiaXMowattGBurrJMCassarKCookeJFraserC. Systematic review of foam sclerotherapy for varicose veins. Br J Surg2007; 94: 925–936.
16.
JL Gillet, M Lausecker, M Sica, JM Guedes and FA Allaert. Is the treatment of the small saphenous veins with foam sclerotherapy at risk of deep vein thrombosis? Phlebology 2013; Epub ahead of print DOI: 10.1177/0268355513497362.
17.
BreuFXGuggenbichlerSWollmannJC. 2nd European Consensus Meeting on Foam Sclerotherapy, 28 – 30 April 2006, Tegernsee, Germany. Vasa2008; 37(Supp 71): 1–32.
18.
Hamel-DesnosCMGilletJ-LDesnosPRAllaertFA. Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phlebology2009; 24: 176–182.
19.
GuexJJ. Les contre-indications de la sclérothérapie, mise à jour 2005. J Mal Vasc2005; 30: 144–149.
20.
RabeEPannier-FischerFGerlachH. Guidelines for sclerotherapy of varicose veins. Dermatol Surg2004; 30: 687–693.
